Value
4.5/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 7.5 |
IDYA · Why this verdict
Why IDEAYA Biosciences (IDYA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline carries high concentration in darovasertib as its lead asset — a single clinical failure, safety signal, or regulatory setback could eliminate the primary driver of the analyst-implied upside without any portfolio offset. Bear case | Darovasertib reports a statistically significant efficacy result (p < 0.05) in a Phase 2 or later clinical trial within 12 months, de-risking the lead asset. | →Stable |
| CounterThe analyst consensus assigns 75% upside to the current price, implying that institutional coverage has modeled the probability-adjusted value of the pipeline and still sees substantial net asset value above current market levels. | ||
The company's fundamental quality sits at the floor of the scale — a Piotroski financial health score of 2 out of 9, no demonstrated economic moat, and zero return on equity — signaling a business that is not yet generating durable economic value and that falls below the minimum quality bar needed to justify a full position. Warnings | If this pillar's concern resolves, the Piotroski F-Score improves above 5 out of 9 for 2 consecutive reporting periods. | →Stable |
| CounterEarly-stage biotechs characteristically score poorly on traditional quality metrics during the R&D-investment phase; the quality floor may simply reflect the development-stage nature of the business rather than a fundamentally broken economic model. | ||
The company is burning cash at 25% of its revenue with no demonstrated path to profitability — the current financial structure depends on continued capital markets access to fund operations, creating ongoing dilution risk for existing shareholders. Quality breakdown | Free cash flow as a percentage of revenue improves above negative 10% for 2 consecutive quarters, indicating the cash burn rate is narrowing toward sustainability. | →Stable |
| CounterA healthy liquidity profile suggests the company is not at immediate risk of running out of cash, which provides a runway for the pipeline to generate clinical results before a capital raise becomes urgent. | ||
A 15% short interest — flagged as justified rather than contrarian — combined with a put/call ratio of 2.86 and implied volatility of 146% indicates sophisticated market participants are positioning in size for a significant downside event. Risk breakdown | Short interest falls below 10% of float within 60 days, indicating the bear case is being abandoned as the clinical pipeline advances. | →Stable |
| CounterHigh short interest in a speculative biotech can reflect convertible or warrant arbitrage structures rather than pure directional bets; a positive clinical catalyst could trigger a rapid short-cover that amplifies any upward move from current levels. | ||
The pipeline carries high concentration in darovasertib as its lead asset — a single clinical failure, safety signal, or regulatory setback could eliminate the primary driver of the analyst-implied upside without any portfolio offset.
→StableBear case
- Expectation
- Darovasertib reports a statistically significant efficacy result (p < 0.05) in a Phase 2 or later clinical trial within 12 months, de-risking the lead asset.
CounterThe analyst consensus assigns 75% upside to the current price, implying that institutional coverage has modeled the probability-adjusted value of the pipeline and still sees substantial net asset value above current market levels.
The company's fundamental quality sits at the floor of the scale — a Piotroski financial health score of 2 out of 9, no demonstrated economic moat, and zero return on equity — signaling a business that is not yet generating durable economic value and that falls below the minimum quality bar needed to justify a full position.
→StableWarnings
- Expectation
- If this pillar's concern resolves, the Piotroski F-Score improves above 5 out of 9 for 2 consecutive reporting periods.
CounterEarly-stage biotechs characteristically score poorly on traditional quality metrics during the R&D-investment phase; the quality floor may simply reflect the development-stage nature of the business rather than a fundamentally broken economic model.
The company is burning cash at 25% of its revenue with no demonstrated path to profitability — the current financial structure depends on continued capital markets access to fund operations, creating ongoing dilution risk for existing shareholders.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of revenue improves above negative 10% for 2 consecutive quarters, indicating the cash burn rate is narrowing toward sustainability.
CounterA healthy liquidity profile suggests the company is not at immediate risk of running out of cash, which provides a runway for the pipeline to generate clinical results before a capital raise becomes urgent.
A 15% short interest — flagged as justified rather than contrarian — combined with a put/call ratio of 2.86 and implied volatility of 146% indicates sophisticated market participants are positioning in size for a significant downside event.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% of float within 60 days, indicating the bear case is being abandoned as the clinical pipeline advances.
CounterHigh short interest in a speculative biotech can reflect convertible or warrant arbitrage structures rather than pure directional bets; a positive clinical catalyst could trigger a rapid short-cover that amplifies any upward move from current levels.
TrendMatrix Research · core thesis
Engine thesis — one sentence
IDEAYA Biosciences carries a 52% analyst-implied upside and favorable near-term price momentum, but the underlying business quality is well below the minimum threshold — with free cash flow burning at 25% of revenue, a Piotroski score of 2 out of 9, and a pipeline concentrated in a single lead asset — making this a high-variance speculative setup where quality concerns outweigh the return potential for most investors.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -25% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.7 |
- ▸Overbought (RSI 90)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 8.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 34%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.4 |
| quality rank | 4.3 |
| growth rank | 5.0 |
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.9 |
| support resistance | 0.1 |
| 52w position | 9.9 |
Risk (lower is worse)
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.6 |
| days to cover | 0.3 |
| volatility | 0.9 |
| put call | 4.7 |
| implied vol | 4.1 |
| debt equity | 1.9 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.2>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (0)
none
Reward-to-Risk
1.11
Upside
+16.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 7.2 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.1<1.5@spot.
The strongest dimensions are Momentum at 7.2, Sentiment at 6.3, and Catalyst at 5.8; the weakest are Quality at 1.5, Risk (lower is worse) at 2.6, and Technical at 3.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.11 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Floor
Trip ifPiotroski F-Score improves above 5 out of 9 for 2 consecutive reporting periods, signaling a material improvement in financial health.
- P2Single Asset Pipeline Concentration
Trip ifDarovasertib reports a statistically significant efficacy result (p < 0.05) in a Phase 2 or later clinical trial within 12 months.
- P3Cash Burning No Profitability
Trip ifFree cash flow as a percentage of revenue improves above negative 10% for 2 consecutive quarters, from the current negative 25% level.
- P4High Short Interest Bearish Positioning
Trip ifShort interest falls below 10% of float within 60 days, indicating the short thesis has been abandoned.